Home
Pharmacovigilance Summit
14 March - 15 March 2011
Pharmacovigilance Summit

The practice of Pharmacovigilance is now more necessary than ever. With the sharp increase in product recalls and litigation cases in recent years, the need for the Pharmaceutical industry to scrutinise each of its new drugs activity and effects has become of paramount importance. 

The potential problems arising from a lack of proper compliance to correct Pharmacovigilance procedures can be catastrophic, ranging from patient sickness and death, to significant damage to a companies financing and reputation.

 

Also running is a post-conference workshop on Wednesday 16th March, 2011

8.30am - 1.30pm - Optimizing Pharmacovigilance in Affiliates

Hosted by; Katja Kusche, Global Head of Safety Science for Mature Product, Hoffmann-La Roche

 

Peter Schiemann, Global Head of Quality Risk Management, Hoffmann-La Roche

 


 

 Stewart Geary, Vice President, Deputy Director, Corporate Regulatory Compliance and Quality Assurance Headquarters, Eisai

 


 

Glyn Belcher, Vice President Drug Safety and Risk Management, Biogen Idec

 

Conference agenda

clock

8:30

Registration & Coffee

clock

8:50

Welcome and introductions

Katja Kusche

Katja Kusche , Safety Science Global Head Mature Products, Hoffmann-La Roche Ltd

clock

9:00

Introduction into the topic

clock

9:30

Presentation of the Roche initiative to optimise PV in affiliates

clock

10:00

Discussion: The interaction between global safety departments and safety affiliate organisations

clock

10:30

Morning coffee

clock

11:00

Role and responsibility of Local Safety Responsible (LSR)

clock

11:30

Exercise/brain storming session

  • Local study activities - Ways to maintain central oversight
  • Cross functional collaboration at the affiliate - How to link to global drug safety
  • Local risk management activities and related assessments
  • clock

    12:30

    Wrap up with summary and questions

    clock

    13:00

    Close of workshop

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Peter Schiemann

    Peter Schiemann, Global Head of Quality Risk Management, Roche Pharma

    clock

    9:10

    PRACTICAL ISSUES IN PHARMACOVIGILANCE INSPECTIONS

    Mechthild Waldeyer

    Mechthild Waldeyer, Drug Safety Management, medac GmbH

  • Case study: A 2010 MHRA PhV Inspection in Stirling, Scotland
  • Internal and external communication
  • Obstacles, surprises, practical recommendations
  • Expenditure of time and costs
  • The importance of team work
  • Be calm and keep your sense of humour!
  • clock

    9:50

    QUALITY RISK MANAGEMENT AS THE QUALITY MANAGEMENT PRINCIPLE

    Peter Schiemann

    Peter Schiemann, Global Head of Quality Risk Management, Roche Pharma

  • What are regulators expecting from a Quality Management System?
  • Quality Management in Pharmacovigilance - How is it done?
  • Preparing for the challenge of risk based inspections
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    MANAGING CLINICAL SAFETY WHEN MANUFACTURING EXPERIENCES SIGNIFICANT GLITCHES

    Glyn Belcher

    Glyn Belcher, Vice President Drug Safety and Risk Management, Biogen Idec

  • Safety monitoring of medicines
  • Implementing an effective response action plan
  • Case studies
  • clock

    11:40

    INSPECTIONS... ARE YOU READY?

    Joanne Webbe

    Joanne Webbe, Associate Director, Drug Safety & Public Health, Gilead Sciences

  • Background to inspections
  • Pharmacovigilance inspections scope
  • Common inspection findings
  • Inspection preparation so you are inspection ready
  • clock

    12:20

    Networking Lunch

    clock

    13:20

    PREPARING FOR AND SURVIVING PV INSPECTIONS

    Mary O'Hare

    Mary O'Hare, Section Director, AstraZeneca

  • Personal inspection experience
  • Review the experience of an MHRA PV Inspection
  • Share what went well and what could be improved
  • Dealing with the aftermath
  • Differences between an MHRA and FDA inspection
  • clock

    14:00

    PANEL DISCUSSION

     

    '‘The impact of new legislation on pharmacovigilance activities and the harmonisation of new regulations'

    Stewart Geary

    Stewart Geary, Regional Safety Director, Eisai

    Glyn Belcher

    Glyn Belcher, Vice President Drug Safety and Risk Management, Biogen Idec

    Catarina Macedo

    Catarina Macedo, Pharmacovigilance Manager, Cancer Research UK

    clock

    15:00

    Afternoon Tea

    clock

    15:30

    PERIODIC SAFETY REPORTING DURING CLINICAL DEVELOPMENT AND THE DSUR

    Stewart Geary

    Stewart Geary, Regional Safety Director, Eisai

  • Purpose and rationale for periodic reporting during clinical development
  • Current regulations for periodic reporting during clinical development:
  • The US IND Annual Report, European Annual Safety Report and Japanese 6-monthly Periodic Report During Development
  • ICH E2F and the DSUR
  • The challenges for preparing the DSUR
  • clock

    16:10

    ROLES AND RESPONSIBILITIES OF SPONSER AND STUDY SITE IN ADVERSE EVENT REPORTING

    Rhoda Molife

    Rhoda Molife, Physician, Institute of Cancer Research

  • Who should do what and when
  • Complexity of patients 'v' rigid nature of adverse event reporting
  • Limitations of SAE reporting forms
  • clock

    16:50

    THE DRAFT ABPI PHARMACOVIGILANCE EXPERT NETWORK GUIDANCE NOTES FOR PHARMACOVIGILANCE IN PATIENT SUPPORT PROGRAMMES

    Esteban Herrero-Martinez

    Esteban Herrero-Martinez, Regulatory Manager, ABPI

  • Reasons for developing the guidance notes
  • Background information on Patient Support Programmes (PSPs)
  • Reactive and proactive approaches in PSPs
  • Recommendations relating to documentation requirements
  • Adverse event collection and reporting requirements
  • clock

    17:30

    Chairman’s Closing Remarks and Close of Day One

    clock

    8:30

    Re-Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Catarina Macedo

    Catarina Macedo, Pharmacovigilance Manager, Cancer Research UK

    clock

    9:10

    DRUG SAFETY IN EARLY PHASE ONCOLOGY TRIALS - CASE STUDIES

    Catarina Macedo

    Catarina Macedo, Pharmacovigilance Manager, Cancer Research UK

  • A non-commercial sponsor’s perspective
  • Early phase oncology trials in patients
  • Recurring themes in case studies:
  • Underlying illness vs. Disease progression vs. Safety signals
  • IMP quality issue with an impact on safety
  • Dealing with independent expert reviews
  • Internal decision making processes and communication
  • clock

    9:50

    OPTIMIZING THE CLINICAL SAFETY CONTRIBUTION TO THE MANAGEMENT OF MANUFACTURING QUALITY ISSUES

    Barbara Donner

    Barbara Donner, Global Head of Safety Science Business Support, Hoffmann-La Roche

  • Approach form medical assessments for product complaints possibly impacting patient’s safety
  • Challenges for Clinical Safety
  • Organizational structure to allow high quality medical assessments
  • Monitoring the safety database for events which may result from product defects
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    RISK MANAGEMENT – WHAT ARE WE LEARNING?

    Deborah Layton

    Deborah Layton, Principal Research Fellow , Drug Safety Research Unit

  • Relationship between safety specification and risk management
  • Developing strategies to answer relevant questions
  • Managing the stakeholders
  • clock

    11:40

    MANAGING BENEFIT/RISK FOR MATURE MEDICINES: A CASE STUDY

    Katja Kusche

    Katja Kusche , Safety Science Global Head Mature Products, Hoffmann-La Roche

  • Mature products' BR can be challenged after decades on the market
  • External researches generating new data and hypotheses
  • Poor quality data in house: Case data from spontaneous reporting and 'historic' dossiers
  • Lack of expertise - Need to reach out to experts in the disease area
  • Limited awareness of the needs for continued support of these products in a development organisation
  • resource constraints while health authority expectations and demands are growing
  • clock

    12:20

    Networking Lunch

    clock

    13:20

    ADVERSE EVENT(S) REPORTING FROM A NON-CLINICAL SAFETY PERSPECTIVE

    George McCormick

    George McCormick, Vice President, Cephalon

  • Relationship between safety specification and risk management
  • What constitutes the necessity to report Adverse Events / Serious Adverse Events (SAE) / Adverse Drug Reactions (ADR) clinically
  • Non-clinical safety assessment in support of clinical safety
  • Traditional endpoints in non-clinical safety testing
  • Predictability of non-clinical safety (animal safety testing) results to drug/chemical-induced safety in humans
  • Classification of toxicities that may be expected during the course of toxicology testing
  • Non-clinical adverse events reporting to domestic and international regulatory agencies 
  • clock

    14:00

    PHARMACOVIGILANCE IN PROMOTION: NECESSITY OR ARGUMENT?

    Michele Sangeleer

    Michele Sangeleer, Pharmacovigilance Manager, Eli Lilly Benelux

  • The legal and deontological requirements for fair safety info in informational/promotional materials for HCPs (including timelines)
  • The challenges of wording and presentation
  • The role of the QPPV and the legal responsible for material review: How far do they have to go?
  • The DDLs and risk management activities integrated in promotion
  • The reaction of European customers (HCP, patients, etc) to safety information
  • clock

    14:40

    Afternoon Tea

    clock

    15:10

    SIGNAL DETECTION IN THE UK

    Shelley Gandhi

    Shelley Gandhi, Unit Manager-Signal Management Group, MHRA

  • Challenges faced by Signal Management systems
  • The tools used for Signal data management at MHRA?
  • Signal Evaluation and Prioritisation
  • Is data quality important for signal generation?
  • What are the future challenges in this area?
  • clock

    15:50

    MANAGEMENT OF SAFETY DATA FROM RELATED RESEARCH ACTIVITIES

    Heide Cunning

    Heide Cunning, Director, Safety Operations, Ortho-McNeil Janssen Scientific Affairs

  • Registration of clinical activities in a company tracking database
  • Minimum requirements for safety data collection
  • Vendor contract and the program protocol/description (if applicable) will contain the applicable safety language
  • Vendor safety training
  • clock

    16:30

    Chairman’s Closing Remarks and Close of Day Two

    Workshops

    Optimizing Pharmacovigilance in Affiliates

    Optimizing Pharmacovigilance in Affiliates

    Copthorne Tara Hotel
    16 March 2011
    London, United Kingdom

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.